DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0152311 A1 Dedhiya Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0152311 A1 Dedhiya Et Al US 2011 O152311A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0152311 A1 Dedhiya et al. (43) Pub. Date: Jun. 23, 2011 (54) NOVEL CRYSTALLINE FORMS OF (30) Foreign Application Priority Data TRANS-7-OXO-6-(SULPHOOXY)-1,6- DIAZABICYCLO3.2.1]OCTANE-2-C Oct. 9, 2009 (FR) ....................................... O904864 ARBOXAMIDE SODUMI SALT Publication Classification (75) Inventors: Mahendra G. Dedhiya, Pomona, NY (US); Sisir Bhattacharya, (51) Int. Cl. Hauppauge, NY (US); Véronique A63L/439 (2006.01) DUCANDAS, VITRY SUR SEINE C07D 47/08 (2006.01) (FR); Alexandre GIULIANI, A6IP3L/04 (2006.01) VILLECRESNES (FR); Valérie (52) U.S. Cl. ......................................... 514/300; 54.6/121 RAVAUX, REYRIEUX (FR); Alain BONNET, CHATEAU-THIERRY (57) ABSTRACT (FR); Alain PRIOUR, PARIS (FR): The present invention relates to novel crystalline forms of Peter Lionel Spargo, DEAL (GB) Sodium salt of trans-7-oxo-6-(Sulphooxy)-1,6-diazabicyclo 3.2.1]octane-2-carboxamide (e.g., NXL-104) thereof. The (73) Assignee: FOREST LABORATORIES present invention relates to compositions comprising a crys HOLDINGS LTD., Hamilton (BM) talline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1, (21) Appl. No.: 12/900,567 6-diazabicyclo3.2.1]octane-2-carboxamide (e.g., NXL 104) alone or in combination with an antibacterial agent (e.g., (22) Filed: Oct. 8, 2010 ceftaroline fosamil). Processes for the preparation of the crys talline forms and methods of treating bacterial infections by Related U.S. Application Data administering the crystalline forms alone or in combination (60) Provisional application No. 61/263,663, filed on Nov. with an antibacterial agent (e.g., ceftaroline fosamil) are also 23, 2009. described. Patent Application Publication Jun. 23, 2011 Sheet 1 of 6 US 2011/0152311 A1 5 10 15 20 25 30 35 40 Two-Theta (deg) Figure 1 Patent Application Publication Jun. 23, 2011 Sheet 2 of 6 US 2011/0152311 A1 2000.000 1800.000 - 1600.000 - 1400.000 - 1200.OOO - 1000.000 - 800,000 - 600,000 400.OOO 200.000 - 0.000 T - O.OOO 1 OOOO 20.OOO 30.000 40.000 50.000 2-theta (deg) Figure 2 Patent Application Publication Jun. 23, 2011 Sheet 3 of 6 US 2011/0152311 A1 16000.000 - 14000.000 - 12000.000 - 10000.000 - 8000.000 - 6000.000 - 4000.000 - 2000.000 - 0.000 0.000 10.000 20,000 30.000 40,000 50.000 60.000 2-theta (deg) Figure 3 Patent Application Publication Jun. 23, 2011 Sheet 4 of 6 US 2011/0152311 A1 6000.000 - 5000.000 - 4000.000 - 3000.000 - 2000.000 - 1OOO.OOO 0.000 - 0.000 1O.OOO 20.OOO 3O.OOO 40.OOO 50.000 60.000 2-theta (deg) Figure 4 Patent Application Publication Jun. 23, 2011 Sheet 5 of 6 US 2011/0152311 A1 3500.000 - 3000.000 - 2500.000 - 2000,000 - 1500.000 - 1OOOOOO - 500.000 - 0.000 - f t 0.000 10.000 20.000 30.000 40.000 50.000 2-theta (deg) Figure 5 Patent Application Publication Jun. 23, 2011 Sheet 6 of 6 US 2011/0152311 A1 1600.000 - 1400.000 - 1200.000 - 1000.000 - 800.000 - 600,000 - 400.000 - 200,000 - 0.000 - T 0.000 10,000 20.000 30.000 40.000 50,000 2-theta (deg) Figure 6 US 2011/0152311 A1 Jun. 23, 2011 NOVEL CRYSTALLINE FORMS OF 0005 U.S. Pat. No. 6,417,175 discloses compounds hav TRANS-7-OXO-6-(SULPHOOXY)-1,6- ing excellent antibacterial activities for a broad range of DIAZABICYCLO3.2.1]OCTANE-2- Gram-positive and Gram-negative bacteria. These com CARBOXAMIDE SODUMI SALT pounds are represented by the general formula: CROSS-REFERENCE TO RELATED APPLICATIONS 0001. This application claims priority under 35 U.S.C. S119, based on French Application No. 0904864 filed on Oct. 2 - - - - 39 9, 2009 and U.S. Provisional Application Ser. No. 61/263,663 NOR 3. 's, filed on Nov. 23, 2009, both of which are hereby incorporated N Y R by reference in their entirety. / y- O D a y FIELD OF THE INVENTION HN O a NS S 0002 The present invention relates to novel crystalline (OOO forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1 octane-2-carboxamide Sodium salt (e.g., NXL-104) and com positions comprising the crystalline forms alone or in com 0006 wherein R'-R, Q, X, Y and n areas defined therein. bination with an antibacterial agent (e.g., ceftaroline 0007 U.S. Pat. No. 6,417,175 discloses methods for pre fosamil). Processes for the preparation of the crystalline paring the compounds, and generically discloses formula forms and methods of treating bacterial infections by admin tions of the compounds, such as aqueous and Saline Solutions istering the crystalline forms alone or in combination with an for injection. One such compound is 7B-2(Z)-ethoxyimino antibacterial agent (e.g., ceftaroline fosamil) are also 2-(5-phosphonoamino-1,2,4-thiadiazole-3-yl)acetamido-3- described. 4-(1-methyl-4-pyridinio)-2-thiazolylhio-3-cephem-4-car BACKGROUND OF THE INVENTION boxylate. 0003 U.S. Pat. No. 7,112,592 discloses novel heterocyclic 0008 U.S. Pat. No. 6,906,055 discloses a chemical genus compounds and their salts, processes for making the com which includes compounds of formula: (HO)2PONH Sn N 21 " N CONH S N N No Nans O)S | O CHCH CO X nH2O pounds and methods of using the compounds as antibacterial 0009 Ceftaroline fosamil is a sterile, synthetic, parenteral agents. One Such compound is sodium salt of trans-7-OXO-6- prodrug cephalosporin antibiotic. The N-phosphonoamino (Sulphooxy)-1,6-diazabicyclo3.2.1]octane-2-carboxamide. water-soluble prodrug is rapidly converted into the bioactive ceftaroline, which has been demonstrated to exhibit antibac Application WO 02/10172 describes the production of azabi terial activity. Ceftaroline fosamil is known as (6R,7R)-7- cyclic compounds and salts thereof with acids and bases, and (2Z)-2-(ethoxyimino)-2-5-(phosphonoamino)-1,2,4-thia in particular, trans-7-OXO-6-sulphoxy-1,6-diazabicyclo3.2. diazol-3-yl)acetamido-3-4-(1-methylpyridin-1-ium-4- 1 octane-2-carboxamide and its pyridinium, tetrabutylam yl)-1,3-thiazol-2-yl)sulfanyl-8-oxo-5-thia-1-azabicyclo[4. monium and sodium salts. Application WO 03/063864 and 2.0oct-2-ene-2-carboxylate. Ceftaroline fosamil may be an U.S. Patent Publication No. 2005/0020572 describe the use of acetic acid hydrous form. compounds including trans-7-OXO-6-(Sulphooxy)-1,6-diaz SH: abicyclo3.2.1]octane-2-carboxamide sodium salt, as B-lac Nt tamase inhibitors that can be administered alone or in, com N1 O n1 | N bination with B-lactamine antibacterial agents. These O references are incorporated herein by reference, in their V 1 v. f N S entirety. HO OH S-N h N 0004 Ceftaroline is a novel parenteral cephalosporin with O abroad spectrum of activity against clinically important com N 21 -- munity-acquired and hospital-acquired Gram-negative and O Gram-positive pathogens including methicillin-resistant Sta O O CHCOOH HO phylococcus aureus and multidrug-resistant Streptococcus pneumoniae. US 2011/0152311 A1 Jun. 23, 2011 0010 U.S. Pat. No. 7,419,973 discloses compositions infections by administering the crystalline forms alone or in comprising ceftaroline fosamil and a pH adjuster, Such as, combination with an antibacterial agent (e.g., ceftaroline fos L-arginine. amil) are also described. 0011 U.S. Pat. Nos. 6,417,175 and 6,906,055 and 7,419, 973 are incorporated herein by reference, in their entirety. BRIEF DESCRIPTION OF THE FIGURES 0012. The present invention relates to the solid state physi (0019 FIG. 1 shows the powder X-Ray diffraction pattern cal properties of trans-7-OXO-6-(Sulphooxy)-1,6-diazabicy of amorphous trans-7-OXO-6-(Sulphooxy)-1,6-diazabicyclo clo3.2.1]octane-2-carboxamide Sodium salt (e.g., NXL 3.2.1]octane-2-carboxamide sodium salt (NXL-104). 104). These properties may be influenced by controlling the 0020 FIG. 2 shows the powder X-Ray diffraction pattern conditions under which trans-7-OXO-6-(Sulphooxy)-1,6-diaz of Form I of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3. abicyclo3.2.1]octane-2-carboxamide Sodium salt (e.g., 2.1]octane-2-carboxamide sodium salt (NXL-104). NXL-104) is obtained in solid form. 0021 FIG. 3 shows the powder X-Ray diffraction pattern 0013 Solid state physical properties include, for example, of Form II of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3. the flowability of the milled solid, rate of dissolution and 2.1]octane-2-carboxamide sodium salt (NXL-104). stability. The physical characteristics are influenced by the 0022 FIG. 4 shows the powder X-Ray diffraction pattern conformation and orientation of molecules in the unit cell, of Form III of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo which defines a particular crystalline form of a Substance. A 3.2.1]octane-2-carboxamide sodium salt (NXL-104). crystalline form may give rise to thermal behavior different (0023 FIG. 5 shows the powder X-Ray diffraction pattern from that of the amorphous material or another crystalline of Form IV of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo form. Thermal behavior is measured in the laboratory using 3.2.1]octane-2-carboxamide sodium salt (NXL-104). techniques such as capillary melting point, thermogravimet 0024 FIG. 6 shows the powder X-Ray diffraction pattern ric analysis (TGA) and differential scanning calorimetry of Form V of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.
Load more

Recommended publications
  • Cefditoren Pivoxil) Tablets 200 and 400 Mg
    SPECTRACEF® (cefditoren pivoxil) Tablets 200 and 400 mg. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION SPECTRACEF® tablets contain cefditoren pivoxil, a semi-synthetic cephalosporin antibiotic for oral administration. It is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active cefditoren. Chemically, cefditoren pivoxil is (-)-(6R,7R)-2,2-dimethylpropionyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy­ iminoacetamido]-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. The empirical formula is C25H28N6O7S3 and the molecular weight is 620.73. The structural formula of cefditoren pivoxil is shown below: cefditoren pivoxil The amorphous form of cefditoren pivoxil developed for clinical use is a light yellow powder. It is freely soluble in dilute hydrochloric acid and soluble at levels equal to 6.06 mg/mL in ethanol and <0.1 mg/mL in water. SPECTRACEF® (cefditoren pivoxil) tablets contain 200 mg or 400 mg of cefditoren as cefditoren pivoxil and the following inactive ingredients: croscarmellose sodium, D-mannitol, hydroxypropyl cellulose, hypromellose, magnesium stearate, sodium caseinate (a milk protein), and sodium tripolyphosphate. The tablet coating contains carnauba wax, hypromellose, polyethylene glycol, and titanium dioxide. Tablets are printed with ink containing D&C Red No. 27, FD&C Blue No. 1, propylene glycol, and shellac. CLINICAL PHARMACOLOGY Pharmacokinetics Absorption Oral Bioavailability Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Redalyc.Patterns of Antimicrobial Therapy in Acute Tonsillitis: a Cross
    Anais da Academia Brasileira de Ciências ISSN: 0001-3765 [email protected] Academia Brasileira de Ciências Brasil JOHN, LISHA J.; CHERIAN, MEENU; SREEDHARAN, JAYADEVAN; CHERIAN, TAMBI Patterns of Antimicrobial therapy in acute tonsillitis: A cross-sectional Hospital-based study from UAE Anais da Academia Brasileira de Ciências, vol. 86, núm. 1, enero-marzo, 2014, pp. 451-457 Academia Brasileira de Ciências Rio de Janeiro, Brasil Available in: http://www.redalyc.org/articulo.oa?id=32730090032 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Anais da Academia Brasileira de Ciências (2014) 86(1): 451-457 (Annals of the Brazilian Academy of Sciences) Printed version ISSN 0001-3765 / Online version ISSN 1678-2690 http://dx.doi.org/10.1590/0001-3765201420120036 www.scielo.br/aabc Patterns of Antimicrobial therapy in acute tonsillitis: A cross-sectional Hospital-based study from UAE LISHA J. JOHN1, MEENU CHERIAN2, JAYADEVAN SREEDHARAN3 and TAMBI CHERIAN2 1Department of Pharmacology, Gulf Medical University, 4184, Ajman, United Arab Emirates 2Department of ENT, Gulf Medical College Hospital, 4184, Ajman, United Arab Emirates 3Statistical Support Facility, Centre for Advanced Biomedical Research and Innovation, Gulf Medical University, 4184, Ajman, United Arab Emirates Manuscript received on December 20, 2012; accepted for publication on October 14, 2013 ABSTRACT Background: Diseases of the ear, nose and throat (ENT) are associated with significant impairment of the daily life and a major cause for absenteeism from work.
    [Show full text]
  • Antibiotic Resistance and Molecular Typing of Pseudomonas Aeruginosa: Focus on Imipenem
    BJID 2002; 6 (February) 1 Antibiotic Resistance and Molecular Typing of Pseudomonas aeruginosa: Focus on Imipenem Ana Lúcia Peixoto de Freitas and Afonso Luis Barth Federal University of Rio Grande do Sul, Pharmacy School, Clinical Hospital of Porto Alegre, Cardiology Institute, Porto Alegre, RS; Catholic University of Pelotas, Pharmacy School, Pelotas, RS, Brazil Susceptibility tests by disk diffusion and by E-test and molecular typing by macrorestriction analysis were performed to determine the relatedness of Pseudomonas aeruginosa isolates from three distinct hospitals. The resistance profile of 124 isolates to 8 antimicrobial agents was determined in three different hospitals, in Porto Alegre, Brazil. Frequencies of susceptibility ranged from 43.9% for carbenicillin to 87.7% for ceftazidime. Cross-resistance data of imipenem-resistant isolates indicated that most (70%) were also resistant to carbenicillin, although 30% remained susceptible to ceftazidime and cefepime. In general, susceptibility profiles were not able to determine relatedness among isolates of P. aeruginosa. On the other hand, molecular typing by macrorestriction analysis demonstrated high discriminatory power and identified 66 strains among 72 isolates of P. aeruginosa. Imipenem-susceptible isolates were all different. However, identical clones of imipenem-resistant isolates were found in two of the hospitals, despite variable response to other antibiotics. No clustering of infection among the different medical centers was observed. In conclusion, clones of P. aeruginosa did not spread among the different hospitals in our city even though related isolates of imipenem- resistant P. aeruginosa were found. Key Words: Pseudomonas aeruginosa, antibiotic resistance, imipenem. Despite improvements in antibiotic therapy, However, nosocomial isolates may easily develop Pseudomonas aeruginosa remains as one of the most resistance to carbapenens due to reduced uptake of prominent Gram-negative bacteria causing hospital- the drug, which leads to outbreaks of multiresistant/ associated infections.
    [Show full text]
  • Ultraviolet-Visible Reference Spectra C
    1536 Ultraviolet-visible Reference Spectra JP XV Butropium Bromide 1 A solution in methanol (1 in 100,000) Butropium Bromide 2 A solution in methanol (1 in 5000) Calcium Folinate An aqueous solution (1 in 100,000) JP XV Ultraviolet-visible Reference Spectra 1537 Camostat Mesilate An aqueous solution (1 in 100,000) Carbamazepine The sample solution obtained in the Assay Carbazochrome Sodium Sulfonate Hydrate An aqueous solution (1 in 100,000) 1538 Ultraviolet-visible Reference Spectra JP XV Carbidopa Hydrate A solution prepared as follows: Dissolve 0.01 g in 250 mL of a solution of hydrochloric acid in methanol (9 in 1000) Carmofur A solution in a mixture of methanol and phosphoric acid-acetic acid-boric acid buffer solution, pH 2.0 (9:1) (1 in 100,000) Carteolol Hydrochloride An aqueous solution (1 in 100,000) JP XV Ultraviolet-visible Reference Spectra 1539 Carumonam Sodium An aqueous solution (3 in 100,000) Cefaclor An aqueous solution (1 in 50,000) Cefadroxil An aqueous solution (1 in 50,000) 1540 Ultraviolet-visible Reference Spectra JP XV Cefalexin An aqueous solution (3 in 100,000) Cefalotin Sodium An aqueous solution (1 in 50,000) Cefapirin Sodium An aqueous solution (3 in 200,000) JP XV Ultraviolet-visible Reference Spectra 1541 Cefatrizine Propylene Glycolate An aqueous solution (1 in 50,000) Cefazolin Sodium An aqueous solution (1 in 50,000) Cefbuperazone Sodium An aqueous solution (1 in 50,000) 1542 Ultraviolet-visible Reference Spectra JP XV Cefditoren Pivoxil A solution in methanol (1 in 50,000) Cefixime A solution in 0.1
    [Show full text]
  • 28912 Oxoid FDA Cartridge Tables:1
    * Adapted in part from CLSI document M100-S23 (M02-A11) : “Disc diffusion supplemental tablesʼʼ Performance standards for antimicrobial susceptibility testing. The complete standard may be obtained from the Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19807. Test Cultures (zone diameters in mm) Antimicrobial Agent Disc Code Potency Resistant Intermediate Susceptible Amikacin AK 30 μg EnterobacteriaceaeK, P. aeruginosa, Acinetobacter spp., and Staphylococcus spp. ≤14 15-16 ≥17 Amoxycillin - Clavulanic Acid AMC 20/10 μg EnterobacteriaceaeE ≤13 14-17 ≥18 Staphylococcus spp.A,Q ≤19 — ≥20 Haemophilus spp.A,Y ≤19 — ≥20 AmpicillinC,n AMP 10 μg EnterobacteriaceaeE and Vibrio choleraef ≤13 14-16 ≥17 Staphylococcus spp.A,Q ≤28 — ≥29 Enterococcus spp.A,V,W,k,m ≤16 — ≥17 Haemophilus spp.Y ≤18 19-21 ≥22 Streptococcus spp. ß-Hemolytic GroupA,d — — ≥24 Ampicillin – Sulbactam SAM 10/10 μg EnterobacteriaceaeE, Acinetobacter spp., and Staphylococcus spp. ≤11 12-14 ≥15 Haemophilus spp.A,Y ≤19 — ≥20 Azithromycin AZM 15 μg Staphylococcus spp., Streptococcus spp Viridans Groupn, ß-Hemolytic Group, and S. pneumoniae) ≤13 14-17 ≥18 Neisseria meningitidisA,i — — ≥20 Haemophilus spp.A — — ≥12 Aztreonam ATM 30 μg EnterobacteriaceaeE ≤17 18-20 ≤21 P. aeruginosa ≤15 16-21 ≥22 Haemophilus spp.A — — ≥26 CAR 100 μg Carbenicillin Enterobacteriaceae ≤19 20-22 ≥23 Pseudomonas aeruginosaP ≤13 14-16 ≥17 CEC 30 μg Cefaclor Enterobacteriaceae and Staphylococcus spp. ≤14 15-17 ≥18 Haemophilus spp.Y ≤16 17-19 ≥20 MA 30 μg Cefamandole EnterobacteriaceaeD,E and Staphylococcus spp. ≤14 15-17 ≥18 CefazolinG KZ 30 μg Staphylococcus spp.
    [Show full text]
  • 00246-2019.Supptables
    1 Table S1. List of ICD-10 codes identifying comorbidities during hospitalization for COPD exacerbation COPD J41, J42, J43, J440, J441, J449 COPD exacerbation J10, J11, J13, J14, J15, J16, J18, J20, J21, J22, J46, J170, J171, J178, J440, J441, J851, J12, A481, B012, B052, B250 Bacterial pneumonia J100, J110, J12, J13, J14, J15, J16, J170, J178, J18, J851, A481 Lung cancer C34 Other malignancy C00-26, C30-33, C37-41, C43-58, C60-76 Diabetes/abnormal glucose tolerance E10-14, R703 Bone fracture/osteoporosis M80-84 Interstitial pneumonia B221, J701, J704, J841, J848, J849, J990, J991, M321, M330, M331, M332, M351 Bronchial asthma J45, J46 Bronchiectasis J40, J41, J42, J47 Pulmonary thromboembolism I26 Mycobacterium infection A150-154, A156-159, A161-162, A165, A168-169, A19, A310, A319 Mycotic infection A420, A43, B37, B380-382, B390-392, B400-402, B410, B420, B440, B441, B449, B460, J172 Cor pulmonare I27 Congestive heart failure E059, I46, I50, I099, I110 Ischemic heart disease I20-25 Tachycardia I47-49, R000, T818 Autoimmune disease M05, M06, M08, M30-35 Stroke I60-64 Liver dysfunction B89, B181, B182, B659, B661, K702, K703, K72, K74, K761, K762, K763, K766, K767 Renal failure E102, E112, E142, I120, N17-19 GERD K21 Constipation or ileus K56, K590 Prostate hypertrophy N40 Abbreviations: COPD, chronic obstructive pulmonary disease; GERD, gastro-esophageal reflux disease 2 Table S2. List of baseline characteristics, comorbidities, and treatments before and during hospitalization for COPD exacerbation Baseline characteristics Sex, fiscal
    [Show full text]
  • AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson
    AMR Open Data Initiative AMR Surveillance in Pharma: a case-study for data sharingauthor by Professor Barry Cookson External Consultant to Project eLibrary • Division of Infection and Immunity, Univ. College London ESCMID• Dept. of Microbiology, © St Thomas’ Hospital Background of “90 day Project” Addressed some recommendations of the first Wellcome funded multi-disciplinary workshop (included Pharma Academia & Public Health invitees: 27thauthor July 2017 (post the Davos Declaration): by 1) Review the landscape of existing Pharma AMR programmes, their protocols,eLibrary data standards and sets 2) Develop a "portal" (register/platform) to access currently available AMR Surveillance data ESCMID Important ©to emphasise that this is a COLLABORATION between Pharma and others Overview of Questionnaire Content • General information - including name,author years active, countries, antimicrobials, microorganisms.by • Methodology - including accreditation, methodology for; surveillance, isolate collection, organism identification, breakpointseLibrary used, • Dataset - including data storage methodology, management and how accessed. ESCMID © 13 Company Responses author 7 by 3 3 eLibrary ESCMID © Structure of register Companies can have different ways of referring to their activities: We had to choose a consistent framework. author Companies Companyby 1 Programmes Programme A Programme B eLibrary Antimicrobials 1 2 3 4 5 company’s product comparator company’s product antimicrobials Programmes canESCMID contain multiple studies (e.g. Pfizer has© single
    [Show full text]
  • Mechanisms of Resistance to P-Lactam Antibiotics Amongst 1993
    J. Med. Microbiol. - Vol. 43 (1999, 30G309 0 1995 The Pathological Society of Great Britain and Ireland ANTI MICROBIAL AGENTS Mechanisms of resistance to p-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993 H. Y. CHEN, ME1 YUAN and D. M. LIVERMORE Department of Medical Microbiology, The London Hospital Medical College, Turner Street, London El 2AD Summary. Antimicrobial resistance among 199 1 Pseudomonas aeruginosa isolates collected at 24 UK hospitals during late 1993 was surveyed. Three-hundred and seventy-two of the isolates were resistant, or had reduced susceptibility, to some or all of azlocillin, carbenicillin, ceftazidime, imipenem and meropenem, and the mechanisms underlying their behaviour were examined. Only 13 isolates produced secondary p-lactamases : six possessed PSE- 1 or PSE-4 enzymes and seven had novel OXA enzyme types. Those with PSE types were highly resistant to azlocillin and carbenicillin whereas those with OXA enzymes were less resistant to these penicillins. Chromosomal p-lactamase derepression was demonstrated in 54 isolates, most of which were resistant to ceftazidime and azlocillin although susceptible to carbenicillin and carbapenems. p-Lactamase-independent “ intrinsic” resistance occurred in 277 isolates and is believed to reflect some combination of impermeability and efflux. Two forms were seen : the classical type, present in 195 isolates, gave carbenicillin resistance (MIC > 128 mg/L) and reduced susceptibility to ciprofloxacin and to all p-lactam agents except imipenem; a novel variant, seen in 82 isolates, affected only azlocillin, ceftazidime and, to a small extent, meropenem. Resistance to imipenem was largely dissociated from that to other p-lactam agents, and probably reflected loss of D2 porin, whereas resistance to meropenem was mostly associated with intrinsic resistance to penicillins and cephalosporins.
    [Show full text]
  • Product Monograph
    Product Monograph PrORB-CEFUROXIME Cefuroxime Axetil Tablets, USP 250 mg and 500 mg cefuroxime/tablet Antibiotic Orbus Pharma Inc. Date of Preparation: February 25, 2009 20 Konrad Crescent Markham, Ontario Control #: 117041 L3R8T4 1 Product Monograph PrORB-CEFUROXIME Cefuroxime Axetil Tablets, USP 250 mg and 500 mg cefuroxime/tablet Antibiotic Actions and Clinical Pharmacology Cefuroxime axetil is an orally active prodrug of cefuroxime. After oral administration, cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to release cefuroxime into the blood stream. Conversion to cefuroxime, the microbiologically active form, occurs rapidly. The inherent properties of cefuroxime are unaltered after its administration as cefuroxime axetil. Cefuroxime exerts its bactericidal effect by binding to an enzyme or enzymes referred to as penicillin-binding proteins (PBPs) involved in bacterial cell wall synthesis. This binding results in inhibition of bacterial cell wall synthesis and subsequent cell death. Specifically, cefuroxime shows high affinity for PBP 3, a primary target for cefuroxime in gram- negative organisms such as E. coli. Comparative Bioavailability Studies A two-way crossover, randomized, blinded, single-dose bioequivalence study was performed on 22 normal, healthy, non-smoking male subjects under fasting conditions. The rate and extent of absorption of cefuroxime axetil was measured and compared following a single oral dose (1 x 500 mg tablet)
    [Show full text]
  • Compositions and Methods to Improve the Oral Absorption of Antimicrobial Agents
    (19) & (11) EP 2 263 654 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 22.12.2010 Bulletin 2010/51 A61K 9/16 (2006.01) A61K 47/36 (2006.01) (21) Application number: 10181335.0 (22) Date of filing: 18.06.2001 (84) Designated Contracting States: (72) Inventors: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU • Choi, Seung-Ho MC NL PT SE TR Salt Lake City, UT 84109 (US) • Lee, Jeoung-Soo (30) Priority: 21.06.2000 US 598089 Salt Lake City, UT 84117 (US) 09.04.2001 US 829405 • Keith, Dennis 16.04.2001 US 283976 P Arlington, MA 02474 (US) (62) Document number(s) of the earlier application(s) in (74) Representative: Williams, Gareth Owen accordance with Art. 76 EPC: Marks & Clerk LLP 01944619.4 / 1 294 361 62-68 Hills Road Cambridge (71) Applicants: CB2 1LA (GB) • Cubist Pharmaceuticals, Inc. Lexington, MA 02421 (US) Remarks: • International Health Management Associates, This application was filed on 28-09-2010 as a Inc. divisional application to the application mentioned Schaumburg, IL 60173 (US) under INID code 62. • The University of Utah Research Foundation Salt Lake City, UT 84108 (US) (54) Compositions and methods to improve the oral absorption of antimicrobial agents (57) The present invention provides compositions sive, an antimicrobial agent, and a cationic binding agent and methods for increasing absorption of antibacterial contained within the biopolymer such that the binding agents, particularly third generation cephalosporin anti- agent is ionically bound or complexed to at least one bacterial agents, in oral dosage solid and/or suspension member selected from the group consisting of the biopol- forms.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]